Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment
Status:
Not yet recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
Investigators hypothesize that ruxolitinib 1.5% cream is an effective therapy for HS
participants through inhibition of inflammatory activity.
Investigators aim to:
- Demonstrate the clinical efficacy of ruxolitinib 1.5% cream in decreasing the clinical
disease activity after 16 weeks of treatment.
- Investigate the impact of ruxolitinib 1.5% cream on skin inflammation through
translational analyses of skin biopsy samples.